1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Simponi (golimumab) (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023

Simponi (golimumab) (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023

Summary

Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints. It affects over seven million individuals in the 10MM covered in this report (US, France, Germany, Italy, Spain, UK, Japan, Australia, China, and India) and the prevalence is expected to grow to just over 8.5 million individuals by 2023. The anti-TNFs have been effective in treating the signs and symptoms of RA and inhibiting progression to erosive bone disease. However, the landscape is quickly changing with the introduction of biosimilars, novel biologics, and a class of oral therapies known as JAK inhibitors, all of which will change the market dynamics between 2013 and 2023. With the anti-TNFs as extremely effective therapies for RA, the market is extremely competitive for new entrants and will undergo further pressure as biosimilars are approved and launch.

J&J’s Simponi (golimumab) is a fully-human IgG1 mAb specific for TNFa. It inhibits TNFa activity, thereby blocking the inflammatory activity of this cytokine and downstream reactions. Simponi is approved for patients with moderate to severe, active RA, and is typically prescribed in conjunction with MTX as a second line of therapy in patients who have failed treatment with another anti-TNF agent, or who have had an unsatisfactory response to MTX.

Scope

- Overview of Rheumatoid Arthritis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Simponi (golimumab) including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Simponi (golimumab) for the top 8 countries from 2013 to 2023.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Australia.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return.
- Stay ahead of the competition by understanding the changing competitive landscape for Rheumatoid Arthritis.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.
- Make more informed business decisions from insightful and in-depth analysis of Simponi (golimumab) performance.
- Obtain sales forecast for Simponi (golimumab) from 2013-2023 in top 8 countries (the US, France, Germany, Italy, Spain, the UK and Japan and Australia).

Table Of Contents

Simponi (golimumab) (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023
1 Table of Contents
2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 10
2.3 Upcoming Related Reports 13
3 Disease Overview 14
3.1 Etiology and Pathophysiology 14
3.1.1 Etiology 14
3.1.2 Pathophysiology 14
3.2 Symptoms 19
3.3 Prognosis 20
3.4 Quality of Life 20
4 Disease Management 21
4.1 Diagnosis and Treatment Overview 21
4.1.1 Diagnosis 21
4.1.2 Treatment Guidelines 23
4.1.3 Leading Prescribed Drugs for the Treatment of RA 33
4.1.4 Clinical Practice 34
5 Competitive Assessment 40
5.1 Overview 40
6 Simponi (golimumab) 42
6.1 Overview 42
6.2 Efficacy 44
6.3 Safety 45
6.4 SWOT Analysis 46
6.5 Forecast 47
7 Appendix 48
7.1 Bibliography 48
7.2 Abbreviations 51
7.3 Methodology 54
7.4 Forecasting Methodology 54
7.4.1 Diagnosed RA Patients 54
7.4.2 Percentage of Drug-Treated Patients 55
7.4.3 General Pricing Assumptions 55
7.4.4 Individual Drug Assumptions 56
7.4.5 Generic and Biosimilar Erosion 57
7.5 Primary Research - KOLs Interviewed for This Report 58
7.6 Primary Research - Prescriber Survey 60
7.7 About the Authors 61
7.7.1 Analyst 61
7.7.2 Reviewer 61
7.7.3 Therapy Area Director 61
7.7.4 Global Head of Healthcare 62
7.8 About GlobalData 63
7.9 Disclaimer 63

1.1 List of Tables

Table 1: Symptoms of RA 19
Table 2: 1987 ACR Diagnostic Criteria for RA 22
Table 3: 2010 ACR/EULAR Diagnostic Criteria for RA 23
Table 4: Treatment Guidelines for RA Used by Each Country in the 10MM 26
Table 5: ACR 2012 Criteria for RA Remission and Low/Moderate/High Disease Activity 29
Table 6: EULAR 2013 Criteria for RA Remission 30
Table 7: Most Prescribed Biologics for RA (After csDMARDs) in the Global Markets, 2014 34
Table 8: Leading Branded Treatments for RA 2014 41
Table 9: Product Profile - Simponi 44
Table 10: Simponi SWOT Analysis, 2014 46
Table 11: Global Sales Forecasts ($m) for Simponi, 2013-2023 47
Table 12: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 60

1.2 List of Figures

Figure 1: Normal Synovial Joint and Synovial Joint with RA 15
Figure 2: Cellular and Cytokine Targets for the Current RA Drugs 18
Figure 3: Disease Management Flowchart for Early RA - ACR 2012 30
Figure 4: Disease Management Flowchart for Established RA - ACR 2012 31
Figure 5: Flowchart for the Management of RA - EULAR 2013 32

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Hepatitis C: Kol Insight

September 2016 $ 8085

Download Unlimited Documents from Trusted Public Sources

Anti-Infective Market in Tanzania

  • December 2016
    9 pages
  • Anti-Infective  

  • Tanzania  

    Africa  

View report >

Therapy and Hormone Market in South Korea

  • December 2016
    4 pages
  • Therapy  

    Hormone  

    Cancer  

  • South Korea  

View report >

Opioid Market in the US

  • December 2016
    14 pages
  • Opioid  

  • United States  

View report >

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.